A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2018
At a glance
- Drugs CDX-0158 (Primary)
- Indications Gastrointestinal stromal tumours; Solid tumours
- Focus Adverse reactions
- Sponsors Celldex Therapeutics; Kolltan Pharmaceuticals
- 23 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
- 23 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.
- 10 Nov 2017 Status changed from recruiting to active, no longer recruiting.